Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (August 2010)

50 slides from Auxilium Pharmaceuticals's investor presentation, Aug 11, 2010

  1. Slide 1: August 2010

    August 2010 (NASDAQ: AUXL) Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,

  3. Slide 3: Opportunities to Build Shareholder Value

    Opportunities to Build Shareholder Value Note: Seeking partners for Transmucosal film product candidates

  4. Slide 4: XIAFLEX (collagenase clostridium histolyticum)

    AlArLEX collagenase clostridium histolyticum

  5. Slide 5: XIAFLEX – Unique Blockbuster Opportunity

    XIAFLEX – Unique Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: — Approved on February 2, for Dupuytren’s Contracture in U.S. — Phase III trial in Peyronie’s disease expected to start by end of • Well-characterized mode of action • World

  6. Slide 6: Dupuytren's Contracture is Debilitating for Patients

    Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery has been th

  7. Slide 7: Treatment Options Historically Limited to Invasive Surgery

    Treatment Options Historically Limited to Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Needle fasciotomy/ aponeurotomy • Amputation • Non-surgical options > Splinting > Physical therapy > Corticosteroids

  8. Slide 8: It Is About the Patient

    It Is About the Patient Pre-XIAFLEX treatment 30 days post-single injection of XIAFLEX Immediately post-operative Intra-operative open fasciectomy Pictures courtesy of Dr. Clayton Peimer

  9. Slide 9: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture

    XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture

  10. Slide 10: A Significant Number of Dupuytren's Contracture Patients Benefited from XIAFLEX

    A Significant Number of Dupuytren’s Contracture Patients Benefited from Treatment with XIAFLEX

  11. Slide 11: Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach

    Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach N=248 N=125 Keith Denkler, M.D. Plast. Reconstr. Surg., 115802, 2005 Dupuytren’s Fasciectomies in 60 Consecutive Digits using lidocaine with epinephrine and no tourniquet Hurst et al. NEJM 2009

  12. Slide 12: XIAFLEX Was Well-Tolerated in Phase III Studies

    XIAFLEX Was Well-Tolerated in Phase III Studies • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days across studies • Serious Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of

  13. Slide 13: Contracture Recurrence Affects Patients

    Contracture Recurrence Affects Patients • The earliest reports of recurrence for surgery were seen in 22% of female and 19% of male Dupuytren’s contracture patients at a mean of months following fasciectomy . Additionally, a rate of up to 34% has been reported within the first years following surger

  14. Slide 14: Two Year Recurrence Rate of 19.3% for XIAFLEX

    Two Year Recurrence Rate of 19.3% for XIAFLEX ® in Dupuytren’s Contracture All Joints MP Joints PIP Joints Patients from All Phase III Studies (n=950) 1,568 Patients Enrolled in Extension Study (n=634) 1,065 Patients Successfully Treated and Enrolled in Extension Study (n=474) 619* 449* Joints with

  15. Slide 15: Launch Update Through July 2010

    Launch Update Through July 2010

  16. Slide 16: Key Objectives for U.S. XIAFLEX Launch in 2010

    Key Objectives for U.S. XIAFLEX Launch in 2010 • Position XIAFLEX as a paradigm changing non-surgical treatment alternative for physicians, payers and patients • Achieve high awareness among targeted physicians and diagnosed patients • Get targeted physicians through the sales cycle – from interest

  17. Slide 17: Targeting the Eligible Patient Population Should Drive U.S. Market Development

    Targeting the Eligible Patient Population Should Drive Development of the U.S. Market to Its Full Potential 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data Based Projections (BESS database used, Medicare 5% database also use

  18. Slide 18: XIAFLEX Launch Strategy is Tailored to Customer Needs

    XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 7,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini

  19. Slide 19: Unique Sales Cycle for Targeted Physicians

    Unique Sales Cycle for Targeted Physicians Physician Interest, Training & Enrollment Successful XIAFLEX XPERIENCE

  20. Slide 20: Changing Treatment Paradigm and Reimbursement Cycle

    Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate Prior to treatment decision Physician must go through: •Awareness •Interest •Training / Enrollment into XIAFLEX XPERIENCE program •Reimbursement education / comfort •Patient Identification / counseling 11 – 21 week

  21. Slide 21: Reimbursement Processes Are New to Target Physicians

    Reimbursement Processes Are New to Target Physicians • Accounts need customized support every step of the way • Miscellaneous J and CPT codes being used; component and bundled approaches are being accepted • C-code for institutional use effective as of July 1, 2010 • CMS has recommended a J-Code for

  22. Slide 22: Over 1,700 physicians and 1,200 sites have enrolled

    Over 1,700 physicians and 1,200 sites have enrolled Feb Mar Apr May Jun Jul PHYSICIANS SITES

  23. Slide 23: Leading Indicators Trending Positively - Cumulative Call Center Volume

    Leading Indicators Trending Positively - Cumulative Call Center Volume

  24. Slide 24: Leading Indicators Trending Positively - Cumulative Unique Sites Ordering

    Leading Indicators Trending Positively - Cumulative unique sites that have ordered XIAFLEX number of sites Mar Apr May Jun Jul

  25. Slide 25: Some Sites Moving from Test Drive to Increasing Usage

    Some Sites Moving from Test Drive to Increasing Usage Injections per Site

  26. Slide 26: ~91% of insured lives have access

    ~91% of insured lives have access

  27. Slide 27: Out of Pocket Costs In Line With Expectations

    Out of Pocket Costs In Line With Expectations % Of Treatment Cost Paid by Patient A significant portion of Medicare patients with a 20% liability have secondary insurance, which may cover a portion of this cost 53% 6% 8% 8% 23% 2% 0% 10% 20% 30% 40% 50% 60% 0% Up to 2% 2.1-9.9% 10-19.9% 20% >20%

  28. Slide 28: Distribution Network is Operating Smoothly

    Distribution Network is Operating Smoothly

  29. Slide 29: Direct to Patient Program Launching

    Direct to Patient Program Launching

  30. Slide 30: Other Patient Programs Launching

    Other Patient Programs Launching • XIAFLEX facebook.com webpage • XIAFLEX.com re-design • XIAFELX and Dupuytren’s contracture WedMD pages • Handraisers.com

  31. Slide 31: We Believe Launch Strategy Is Sound

    We Believe Launch Strategy Is Sound: • Product efficacy and safety are consistent with clinical data • Access to targeted physicians is good • Usage is characterized by “test driving”, which is typical for paradigm changing treatment • Payers willing to provide access to drug and procedures • All di

  32. Slide 32: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated

    Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence Based on literature, ~ 6M to 11M patients in U.S. have a Dupuytren’s pit, nodule or cord, but only ~ 300,000 new patients annually diagnosed in U.S. • Sustainable patient pool New patients within an agei

  33. Slide 33: XIAFLEX I.P. Position for Dupuytren's Contracture

    XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug designation granted on May 23, 1996 provides exclusivity for 7 years post-approval in February 2010 • Market Exclusivity expected in U.S. for 12 years post-approval, per 2010 Patient Protection and Affordable Care Act • Market Excl

  34. Slide 34: Peyronie's Disease is a Devastating Disorder

    Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/

  35. Slide 35: Peyronie's Disease - an Unmet Medical Need

    Peyronie’s Disease - an Unmet Medical Need • Prevalence of Peyronie’s disease is estimated at 1 in 20 adult men > Actual prevalence may be higher, based on autopsies • Prevalence rate increases with age > The average age of disease onset is 53 years • High association with other diseases such as: >

  36. Slide 36: Current Surgical Options Are the Treatment of Last Resort

    Current Surgical Options Are theTreatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated

  37. Slide 37: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Success

    Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a

  38. Slide 38: Promising Phase IIb Data in Peyronie's Disease

    Promising Phase IIb Data in Peyronie’s Disease • Overall – Significant XIAFLEX effect – Reduction of penile curvature – Improvement in Peyronie’s Disease Bother (PRO Domain) • XIAFLEX With Modeling – Significant effect in both penile curvature and Peyronie’s disease bother endpoints • XIAFLEX Withou

  39. Slide 39: Strategic Partnership with Pfizer for XIAFLEX in EU

    Strategic Partnership with Pfizer for XIAFLEX in EU • Strong working relationship with goal to obtain EMA approval • Auxilium is primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. • Pfizer is primarily responsible for: European

  40. Slide 40: Testim 1% Testosterone Gel

    Testim ® 1% Testosterone Gel

  41. Slide 41: Testim Maintains Double-Digit Growth in TRT Market

    Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad

  42. Slide 42: Patient Results Were Proven in Clinical Studies

    Patient Results Were Proven in Clinical Studies • 16 clinical studies involving approx. 1,800 patients > largest placebo-controlled study ever conducted • Clinical trial of Testim ® vs. AndroGel ® > Testim provides 30% higher testosterone absorption (p<0.001)

  43. Slide 43: Gels Continue to Drive Significant Growth in TRT Marketplace

    Gels Continue to Drive Significant Growth in TRT Marketplace Gel Segment Growth ($) June 2010 L12M: 29.6%

  44. Slide 44: Continuing Track Record of Consistent Revenue Growth

    Continuing Track Record of Consistent Revenue Growth

  45. Slide 45: Testim Patent Coverage

    Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use claims for

  46. Slide 46: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part

    FDA Has Granted Our Citizen's Petition In Part And Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic vers

  47. Slide 47: 2010 Financial Results and 2010 Guidance

    Testim Revenues $91.6 $72.1 $185-195 XIAFLEX Revenues $4.3 $1.8 N/A R&D Expense* $19.6 $27.3 $50-60 SG&A Expense* $77.3 $55.8 $160-170 Net Loss ($22.1) ($26.0) N/A Stock – Based Comp Expense (* included) $8.4 $9.4 $22-25 Cash & Cash Equivalents $165.0 2010 Financial Results and 2010 Guidance ($ Mill

  48. Slide 48: Auxilium's Plan to Provide Visibility on XIAFLEX Launch

    Auxilium’s Plan to Provide Visibility on XIAFLEX Launch • For 3Q 2010, we anticipate that XIAFLEX net revenues will be in the range of $5.5 million to $6.5 million, including approximately $1.1 million in revenue recognized from milestones previously received under the Pfizer contract. • We will con

  49. Slide 49: Strategic Priorities in 2010

    Strategic Priorities in 2010 • Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; • Support Pfizer in the ongoing regulatory review of the EU Dupuytren’s submission and prepare for their eventual launch; • Commence phase III for XIAFLEX in Peyronie’s disease by year end of 2010;

  50. Slide 50: Opportunities to Build Shareholder Value

    Opportunities to Build Shareholder Value Note: Seeking partners for Transmucosal film product candidates

Auxilium Pharmaceuticals — Investor Presentation (August 2010) on 6ix